This article is only available in the PDF format. Download the PDF to view the article, as well as its associated figures and tables.
Those who are familiar with the policy of the Josiah Macy, Jr., Foundation in organizing round table discussions on various clinical phenomena will be pleased to see the "Transactions of the Third Conference on Blood Clotting and Allied Problems." Those who are unfamiliar with the Macy policy may be surprised at the informality of much of the text but cannot fail to be impressed by the unique approach to clinical problems. The opportunity for men from various disciplines to present different aspects of the problem and to ply each other with questions is perhaps not unique in the scientific world, but it reaches a refreshingly informal peak in the Macy Conferences. The "Transactions of the Third Conference on Blood Clotting" includes discussions on a clinical and experimental level of such new anticoagulants as phenylindanedione, ethyl biscoumacetate (tromexan® ethyl acetate) and paritol® (a sulfated mannuronic acid), the first two
Transactions of Third Conference on Blood Clotting and Allied Problems, 1949. AMA Arch Intern Med. 1951;88(1):132. doi:10.1001/archinte.1951.03810070142012
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: